Reading view
Linking Dispense Data to Electronic Health Orders: Tutorial for Querying Commercial Pharmacy Databases to Support Systemwide Quality Improvement
Development and Preliminary Evaluation of a Conversational Agent Delivering Problem-Solving Therapy for Family Caregivers of Children With a Chronic Health Condition: Multiphase Mixed Methods Study
Authors’ Reply: Clarifying the Comparative Interpretation and Clinical Implications of Radiomics-Based AI for Pathological Response Prediction
Same-Patient, Same–Time Point Evidence for Radiomics Benchmarking
User Experiences With a Social Robot for Cardiometabolic Risk Assessment in a Community Setting in Uppsala, Sweden: Qualitative Semistructured Interview Study
AI and the Reproduction of Health Inequity: Redistribution-Translation-Accumulation Framework
Effects of Virtual Reality on Pain, Anxiety, and Fear During Thyroid Fine-Needle Aspiration Biopsy: Open-Label Randomized Controlled Trial
Metal–organic framework nanovaccines for systemic tumour regression
Nature Biomedical Engineering, Published online: 06 October 2026; doi:10.1038/s41551-026-01786-5
A nanoscale metal–organic framework (MOF)-based cancer vaccine platform enables coordinated antigen presentation and innate immune activation, resulting in tumour regression, immune memory and protection against metastasis.Realignment of representational drift in mouse visual cortex via flexible electrode arrays
Nature Biomedical Engineering, Published online: 06 October 2026; doi:10.1038/s41551-026-01780-x
A long-term flexible electrode array system stably tracks individual neurons for months, revealing intrinsic drift in visual evoked neural activity and potentiating durable cross-session and cross-animal decoding.Virtual reality for cognitive and neuropsychiatric outcomes in mild cognitive impairment and dementia: a network meta-analysis
npj Digital Medicine, Published online: 06 October 2026; doi:10.1038/s41746-026-03367-x
Virtual reality for cognitive and neuropsychiatric outcomes in mild cognitive impairment and dementia: a network meta-analysisCalibrated AI approach to pharmacovigilance using FAERS
npj Digital Medicine, Published online: 06 October 2026; doi:10.1038/s41746-026-03273-2
Calibrated AI approach to pharmacovigilance using FAERSLLM-derived narrative metrics in chronic pain: convergent validity and novel cognitive constructs
npj Digital Medicine, Published online: 06 October 2026; doi:10.1038/s41746-026-03359-x
LLM-derived narrative metrics in chronic pain: convergent validity and novel cognitive constructsA legal and ethical architecture for a surgical video data registry in England
npj Digital Medicine, Published online: 06 October 2026; doi:10.1038/s41746-026-03345-3
A legal and ethical architecture for a surgical video data registry in EnglandMachine learning classification of digital exclusion in ageing populations across five international cohorts
npj Digital Medicine, Published online: 06 October 2026; doi:10.1038/s41746-026-03268-z
Machine learning classification of digital exclusion in ageing populations across five international cohortsSPIRIT-CONSORT-ELM: element-level annotated dataset and large language model approach for assessing randomized controlled trial reporting
npj Digital Medicine, Published online: 06 October 2026; doi:10.1038/s41746-026-03318-6
SPIRIT-CONSORT-ELM: element-level annotated dataset and large language model approach for assessing randomized controlled trial reportingStage-Based Model of User Engagement Patterns in an Online Health Community for Cardiovascular Disease Management: Qualitative Interview Study
A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring
J Liq Biopsy. 2026 Sep 19;14:100496. doi: 10.1016/j.jlb.2026.100496. eCollection 2026 Dec.
ABSTRACT
BACKGROUND: Circulating tumor DNA (ctDNA) analysis has revolutionized minimal residual disease (MRD) monitoring, but conventional tumor-informed amplicon-based sequencing (AMP) is limited by the narrow variant capacity and diversity. Hybrid capture-based sequencing (HYB) is more versatile and enables both tumor-informed and tumor-naïve liquid biopsy profiling.
METHODS: We analytically validated the performance of our novel HYB workflow and VarSURE variant calling pipeline, using reference standards (n = 6), plasma samples of cancer patients (n = 75) and healthy donors (n = 90). Genome-wide (GW) non-mutation features including copy number alterations, fragmentomics, and end-motif signatures were also evaluated to enhance ctDNA-MRD detection. Clinical performance was directly compared against our legacy AMP method (K-TRACK, Gene Solutions), using pre-treatment blood samples across multiple cancers (n = 290) and longitudinal cohorts of colorectal cancer (CRC, n = 64), and hepatocellular carcinoma (HCC, n = 47).
RESULTS: Optimal parameters to maximize assay performance included single-stranded DNA ligation technology, cfDNA input ≥ 15 ng, post-UMI sequencing depth ≥ 2500X, and high number of tracked mutations. In the tumor-informed setting, the HYB workflow was modestly better than the AMP method in detection of pre-treatment ctDNA; addition of GW features was marginally beneficial except in lung cancer. Surveillance ctDNA determined by the HYB workflow had superior sensitivity to predict recurrence in both CRC (AMP: 90.0%, HYB: 100%) and HCC (AMP: 80.0%, HYB: 96.0%). In the tumor-naïve setting, the performance gap widened significantly, and the combined HYB and GW workflow showed the highest performance in baseline ctDNA detection across all cancers, and achieved sensitivity of 90.0% and 92.0% to detect recurrence in CRC and HCC respectively.
CONCLUSIONS: The new methodology offers a streamlined and scalable solution for both comprehensive liquid biopsy profiling and longitudinal MRD tracking in routine clinical practice.
PMID:42830887 | PMC:PMC13634064 | DOI:10.1016/j.jlb.2026.100496
Role of circulating tumour DNA in predicting complete clinical response and local regrowth after total neoadjuvant therapy for rectal cancer: meta-analysis
BJS Open. 2026 Sep 4;10(5):zrag142. doi: 10.1093/bjsopen/zrag142.
ABSTRACT
BACKGROUND: Non-operative management after total neoadjuvant therapy (TNT) has emerged as a potential strategy for patients with locally advanced rectal cancer (LARC) achieving clinical complete response (cCR). Circulating tumour DNA (ctDNA) has been proposed as a systemic biomarker to augment response assessment, but its role in predicting cCR and local regrowth remains uncertain.
METHODS: A systematic review and meta-analysis were performed of studies evaluating ctDNA dynamics in patients with LARC undergoing TNT. PubMed, EMBASE, and Web of Science databases were searched from database inception to 31 March 2026. Primary outcomes were the association between post-TNT ctDNA status and cCR and sustained cCR. Pooled odds ratios (ORs) were calculated using a random-effects model.
RESULTS: Six studies comprising 597 patients were included. ctDNA negativity following TNT was associated with higher likelihood of cCR (OR 8.01; 95% confidence interval (c.i.) 1.43 to 44.90; I2 = 27.0%). The association with sustained cCR was not statistically significant (OR 3.46; 95% c.i. 0.03 to 394.64; I2 = 59.9%). Across studies, post-TNT ctDNA positivity was associated with inferior disease-free, distant recurrence-free, and progression-free survival. ctDNA demonstrated high specificity and positive predictive value for residual disease, but low sensitivity for the detection of residual local disease and local regrowth, with a substantial proportion of patients with residual tumour remaining ctDNA negative at restaging.
CONCLUSION: Post-TNT ctDNA positivity may identify patients at increased risk of adverse oncological outcomes. However, ctDNA negativity was not consistently associated with the absence of residual local disease, limiting its utility as an independent determinant of organ preservation eligibility. ctDNA should be interpreted as a complementary tool for systemic risk stratification alongside established anatomical assessment.
PMID:42832577 | DOI:10.1093/bjsopen/zrag142